LncRNA PAINT is associated with aggressive prostate cancer and dysregulation of cancer hallmark genes.
EMT
LncRNA
RNA-Seq
apoptosis
drug resistance
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
17 Mar 2021
17 Mar 2021
Historique:
revised:
26
02
2021
received:
05
10
2020
accepted:
03
03
2021
pubmed:
18
3
2021
medline:
18
3
2021
entrez:
17
3
2021
Statut:
aheadofprint
Résumé
Long noncoding RNAs (lncRNAs) play regulatory role in cellular processes and their aberrant expression may drive cancer progression. Here we report the function of a lncRNA PAINT (prostate cancer associated intergenic noncoding transcript) in promoting prostate cancer (PCa) progression. Upregulation of PAINT was noted in advanced stage and metastatic PCa. Inhibition of PAINT decreased cell proliferation, S-phase progression, increased expression of apoptotic markers, and improved sensitivity to docetaxel and Aurora kinase inhibitor VX-680. Inhibition of PAINT decreased cell migration and reduced expression of Slug and Vimentin. Ectopic expression of PAINT suppressed E-cadherin, increased S-phase progression and cell migration. PAINT expression in PCa cells induced larger colony formation, increased tumor growth and higher expression of mesenchymal markers. Transcriptome analysis followed by qRT-PCR validation showed differentially expressed genes involved in epithelial mesenchymal transition (EMT), apoptosis and drug resistance in PAINT-expressing cells. Our study establishes an oncogenic function of PAINT in PCa.
Identifiants
pubmed: 33729568
doi: 10.1002/ijc.33569
pmc: PMC9211384
mid: NIHMS1807469
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R21 CA226611
Pays : United States
Organisme : NIH HHS
ID : R21CA226611
Pays : United States
Informations de copyright
© 2021 UICC.
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Am J Pathol. 2011 Jul;179(1):400-10
pubmed: 21703419
Oncotarget. 2016 Aug 2;7(31):50315-50332
pubmed: 27385093
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16654-9
pubmed: 23011797
Mol Biol Cell. 2008 Nov;19(11):4875-87
pubmed: 18799618
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Br J Cancer. 2015 Jan 6;112(1):4-8
pubmed: 25203520
Urol Oncol. 2013 Nov;31(8):1751-60
pubmed: 22421353
Trends Genet. 2018 Feb;34(2):142-157
pubmed: 29249332
Mol Cancer. 2011 Nov 10;10:139
pubmed: 22074556
Cancer Res. 2003 May 1;63(9):2306-11
pubmed: 12727854
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4631-E4640
pubmed: 28533408
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Oncotarget. 2016 Nov 8;7(45):73739-73753
pubmed: 27650539
Mol Cell Biochem. 2019 Sep;459(1-2):21-34
pubmed: 31073887
Cell Death Discov. 2019 Sep 30;5:139
pubmed: 31583122
Cell Rep. 2015 Oct 6;13(1):209-221
pubmed: 26411689
Nat Rev Urol. 2017 Nov;14(11):683-696
pubmed: 28895566
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
Oncogene. 2015 Jan 29;34(5):546-57
pubmed: 24469056
Sci Rep. 2019 Jul 10;9(1):10003
pubmed: 31292507
Mol Cell Biochem. 2016 Jan;411(1-2):11-21
pubmed: 26369530
Oncotarget. 2017 Sep 21;8(50):87675-87683
pubmed: 29152111
PLoS One. 2017 Nov 15;12(11):e0186852
pubmed: 29141018
J Natl Cancer Inst. 1993 Feb 3;85(3):200-6
pubmed: 8423624
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Med Sci Monit. 2019 May 02;25:3238-3246
pubmed: 31044775
Development. 2016 Dec 1;143(23):4291-4300
pubmed: 27899506
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
Mol Cancer Ther. 2010 May;9(5):1318-27
pubmed: 20388735
Pharmacogenomics J. 2013 Apr;13(2):110-20
pubmed: 22231567
J Cell Biochem. 2001;81(1):56-67
pubmed: 11180397
Onco Targets Ther. 2018 Jul 31;11:4431-4442
pubmed: 30104884
Mol Med Rep. 2016 Jan;13(1):778-86
pubmed: 26648419
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Cell Physiol Biochem. 2015;37(6):2209-20
pubmed: 26610246
J Clin Oncol. 2019 May 10;37(14):1159-1168
pubmed: 30860948
Nat Biotechnol. 2015 Mar;33(3):243-6
pubmed: 25748911
Cell Death Dis. 2017 Oct 5;8(10):e3060
pubmed: 28981098
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
BMC Med Genomics. 2008 May 19;1:17
pubmed: 18489756
Curr Drug Targets. 2012 Sep 1;13(10):1308-23
pubmed: 22746994
Nat Genet. 2013 Nov;45(11):1392-8
pubmed: 24076601
BMC Cancer. 2019 May 6;19(1):423
pubmed: 31060542
Biochim Biophys Acta. 2014 Jun;1843(6):1216-24
pubmed: 24632071
Nat Rev Mol Cell Biol. 2018 Mar;19(3):143-157
pubmed: 29138516
J Clin Invest. 2016 Aug 1;126(8):2775-82
pubmed: 27479746
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
Nucleic Acids Res. 2013 Apr 1;41(6):e74
pubmed: 23335781
J Pathol. 2015 Sep;237(1):25-37
pubmed: 25904364
Mol Endocrinol. 2012 Sep;26(9):1496-507
pubmed: 22745193